SynRx Therapeutics develops first-in-class anti-tumor drugs targeting DNA damage repair pathways through synthetic lethality approaches, specifically designed to exploit the vulnerabilities of cancer cells. The company addresses the need for effective oncology solutions by advancing multiple novel drug candidates that selectively kill tumor cells while minimizing harm to normal tissues.
Funding
Funding not disclosed
Founders
Product
Problem
Many cancers develop resistance to existing treatments by exploiting DNA damage repair (DDR) pathways, allowing them to survive and proliferate despite chemotherapy or radiation. Current oncology drugs often lack the specificity to target tumor cells effectively, leading to significant toxicity and off-target effects in healthy tissues. There is a need for novel therapeutics that can selectively disrupt DDR mechanisms in cancer cells, minimizing harm to normal cells and overcoming resistance mechanisms.
Solution
SynRx Therapeutics is developing a portfolio of first-in-class anti-tumor drugs that target DNA damage repair pathways, leveraging synthetic lethality to selectively kill cancer cells. By focusing on vulnerabilities within cancer cells' DDR mechanisms, SynRx's drug candidates aim to disrupt tumor growth while sparing healthy tissues. The company's approach involves identifying and validating novel drug targets within the DDR pathway and developing small molecule inhibitors that exploit these vulnerabilities. These inhibitors are designed to selectively induce cell death in tumors with specific DDR deficiencies, offering a more targeted and effective approach to cancer treatment.
Target Audience
SynRx Therapeutics' primary target audience includes patients with cancers that exhibit dysregulation of DNA damage repair pathways, as well as oncologists and researchers seeking more effective and targeted cancer therapies.
Features
- Focus on novel targets within the DNA damage repair (DDR) pathway.
- Development of small molecule inhibitors designed for synthetic lethality.
- Selective targeting of tumor cells with DDR deficiencies to minimize off-target effects.
- Multiple drug candidates in preclinical development, with some undergoing lead optimization.
- Utilization of virtual screening and laboratory testing for compound identification.
- Platform based on research from Westlake University's School of Life Sciences.